How Imatinib Transformed Leukemia

Can Genetic Alterations Cause Cancer?

In the 1950s, scientists had a limited understanding of how genes influence cancer.

“It was a time when most investigators did not think that tumors were caused by genetic mutations,” wrote Peter Nowell, M.D., then a researcher at the University of Pennsylvania.

Despite that paradigm, some scientists wondered: Can genetic alterations cause cancer? However, they lacked consistent evidence to support this hypothesis.

During that time, Dr. Nowell spent his days peering into the microscope, studying cancer cells from people with a type of blood cancer called chronic myelogenous leukemia (CML). Back then, patients diagnosed with CML were basically handed a death sentence. The available treatments were harsh, invasive, and not very effective.

Despite the popular belief that cancer was not caused by genetic changes, Dr. Nowell was interested in the chromosomes (structures that carry genetic information) of leukemia cells.

He searched through the University of Pennsylvania for someone who shared this interest, but came up empty-handed. Luckily someone introduced him to David Hungerford, Ph.D., then a graduate student at the Fox Chase Cancer Center in Philadelphia. Dr. Hungerford was studying chromosomes for his graduate thesis, so the two decided to collaborate.

Discovery of the Philadelphia Chromosome in Leukemia

In 1960, Drs. Nowell and Hungerford examined cancer cells from two patients with CML and noticed something peculiar—one of the 46 chromosomes was abnormally short. Though they had no clues as to how the short chromosome was created, or what its function was, the genetic alteration piqued their interest.

Curious to know if the small chromosome was a common feature in CML, they eagerly examined leukemia cells from more people with CML. Sure enough, they found seven more patients who had the same abnormal chromosome.

The tiny chromosome was later named “the Philadelphia chromosome” after the city where Drs. Nowell and Hungerford discovered it. Further research showed that 95% of patients with CML have the Philadelphia chromosome.

It wasn’t until the 1970s—when techniques for studying DNA improved—that researchers realized the Philadelphia chromosome forms when two chromosomes break and the pieces swap places.

A few years later, Nora Heisterkamp, M.D., (then a researcher at NCI) and her colleagues discovered that when the Philadelphia chromosome forms, two genes that are normally separated get fused together. The hybrid (called a fusion gene) is known as BCR-ABL.

Owen Witte, M.D., and his colleagues at the University of California, Los Angeles, later proved that when BCR-ABL forms in blood cells, it causes CML.

Illustration of translocation, which is when pieces from two different chromosomes trade places and create changed chromosomes. For CML, part of chromosome 9 replaces part of chromosome 22 and creates the Philadelphia chromosome

CML is caused by one translocation that creates a singular mutation, the BCR-ABL fusion gene or Philadelphia chromosome.

The discovery of the Philadelphia chromosome and BCR-ABL, supported in part by NCI, demonstrated for the first time that a genetic alteration could cause cancer.

Imatinib: A Therapy Targeted Against Leukemia

In the 1990s, Brian Druker, M.D., of Oregon Health and Science University, was hoping to find a treatment for CML that, unlike chemotherapy, could kill cancer cells but leave healthy cells intact.

Maybe patients with CML could be treated with a drug that blocks BCR-ABL, he hypothesized. He reasoned that because healthy cells do not have BCR-ABL, they should not be affected by such a treatment.

Working with Nicholas Lydon, M.D., who led a drug discovery group at a pharmaceutical company, Dr. Druker searched through an extensive collection of compounds for one that could do just that.

Remarkably, the pair identified a drug that was incredibly good at killing CML cells. In fact, it was far better than any other drug they investigated. The drug, named STI-571 and later renamed imatinib (Gleevec), blocks the activity of the BCR-ABL fusion protein.

In 1998, Dr. Druker and his colleagues tested imatinib in a phase 1 clinical trial partially funded by NCI. The drug caused cancer to disappear in the majority of patients with CML that was in the early, or chronic, phase of the disease. Five years later, 98% of patients from this trial were still in remission.

“For a lot of people, Gleevec was simply too good to be true. But these once-dying patients were getting out of bed, dancing, going hiking, doing yoga. The drug was amazing,” Dr. Druker said in a 2009 interview with The New York Times.

Subsequent clinical trials found similar results in larger groups of patients. And compared with the standard treatments for CML, imatinib also improved patients’ quality of life and caused fewer side effects.

In 2001, the Food and Drug Administration (FDA) approved imatinib to treat patients with CML that has the Philadelphia chromosome. Today, someone with CML who is in remission after two years of imatinib treatment has the same life expectancy as someone who doesn’t have cancer.

In addition to transforming the outcome for patients with CML, the discovery of imatinib helped establish a group of cancer drugs, called targeted therapies, that are designed to attack cancer cells with specific genetic abnormalities.

Targeted therapies have immensely changed how cancer is studied and treated, and have fostered the precision medicine approach: treatment tailored to the unique genetic changes in an individual’s cancer cells.

  • Updated: April 11, 2018

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “How Imatinib Transformed Leukemia Treatment and Cancer Research was originally published by the National Cancer Institute.” original source


We also sell Generic Valdoxan. We offer Agomelatine 25mg at best prices from India, for future details please visit following website.

Drug similar to Gleevec

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule–a fusion of two normal cell proteins–that fueled a tumor’s growth.

A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown. A team led by Antonio Iavarone, MD, professor of neurology and of pathology and cell biology, Institute for Cancer Genetics, previously discovered that a fusion of two proteins (present only in cancer cells and different from the two in CML) drives some cases of glioma, a common form of brain cancer.

The team’s most recent study, published in Clinical Cancer Research, looked closely at two patients affected by recurrent glioblastoma with the fused proteins, in a first in-human trial of a drug that targets half of the fusion protein. Those patients, the researchers found, responded particularly well to the drug, with clinical improvement and radiological tumor reduction. The responses lasted 115 and 134 days, respectively.

“This suggests that if we developed a drug that hits the fused protein more precisely, while leaving normal cells alone, we may get even better results,” said Dr. Iavarone. “The real test of that will have to wait for the development of such a drug and the clinical trials.”

The study also found the fused protein in a significant fraction of the 795 glioma cases they examined, indicating that a smart drug that targets the fused proteins could have a meaningful impact.


We also sell another anti cancer medicines – Sorafenib and Gefitinib, this is generics for Nexavar and Iressa, you can find additional information about this drugs by following links for Sorafenib (link) & Iressa (link) 

What is Imatinib?

Imatinib (INN), marketed by Novartis as Gleevec (U.S.) or Glivec (Europe/Australia/Latin America) & markered by Natco as Veenat (India), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Like all tyrosine-kinase inhibitors, imatinib works by preventing a tyrosine kinase enzyme, in this case BCR-Abl, from phosphorylating subsequent proteins and initiating the signaling cascade necessary for cancer development, thus preventing the growth of cancer cells and leading to their death by apoptosis. Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy—only cancer cells are killed through the drug’s action. In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.

Imatinib has been cited as the first of the exceptionally expensive cancer drugs, costing $92,000 a year. Doctors and patients complain that this is excessive, given that its development costs have been recovered many times over, and that the costs of synthesizing the drug are orders of magnitude lower. In the USA, the patent protecting the active principal will expire on 4 January 2015 while the patent protecting the beta crystal form of the active principal ingredient will expire on 23 May 2019.

The developers of imatinib were awarded the Lasker Award in 2009 and the Japan Prize in 2012.


Our company sell various medication, for example, we offer medicines for erectile dysfunction: Suhagra or Cenforce